GSK's two-drug HIV treatment meets main goal in late stage studies

[June 14, 2018] (Reuters) - GlaxoSmithKline said on Thursday that its two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies.

The studies were designed to evaluate the safety and efficacy of the two-drug combination, which is aimed at lessening the side effect of current treatments that combine three or four medicines.

The safety results for the new HIV treatment, a fixed-dose once-daily tablet that combines two previously approved drugs, dolutegravir and rilpivirine, were consistent with the product labeling for the medicines, GSK's majority owned ViiV Healthcare said.

(Reporting by Arathy S Nair in Bengaluru; Editing by Alexander Smith)

[© 2018 Thomson Reuters. All rights reserved.]

Copyright 2018 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.